Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.20 | N/A | +51.12% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.20 | N/A | +51.12% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to growth. They emphasized the importance of product expansion in future strategies.
We are pleased with our EPS performance this quarter.
Our focus remains on expanding our product offerings.
Repligen Corp's strong EPS performance, beating expectations by over 51%, contributed to a positive stock reaction, with shares rising nearly 8%. The lack of revenue data leaves some uncertainty, but the management's focus on growth and product expansion suggests a strategic direction moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERISK ANALYTICS INC A
Feb 20, 2018